# US 2004/0023204 A1 · Peptides which enhance transport across tissues and methods of identifying and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0023204 A1
- Document ID: US20040023204A1
- Status: Published application
- Kind: A1
- Application number: 10/104,603
- Filed: 2002-03-22
- Published: 2004-02-05
- Earliest claimed: 1996-11-08
- Assignees: EUSA Pharma Ltd.
- Inventors: Daniel Joseph O'Mahony; Vernon L. Alvarez; Michela Seveso
- Web page: https://patentgrep.com/patent/US20040023204A1

## CPC

- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- A61K 9/167: {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61P 5/48: of the pancreatic hormones
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- Y10S 977/805: Containing drug
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue. A predetermined amount of phage from a random phage library or a preselected phage library is administered in vivo or in situ to a site in an animal, such as into the gastro-intestinal tract. At a predetermined time, the phage which is transported across a tissue barrier is harvested at a harvesting site, such as in portal or systemic blood or brain tissue, which is separated from the site of administration by the tissue barrier to select transported phage. This transported phage is amplified in a host. This cycle of events is repeated (using the transported phage produced in the most recent cycle) a predetermined number of times to obtain a selected phage library containing phage which can be transported from the site of administration to the harvesting site. The identity of at least one peptide coded by phage in the selected phage library is determined to identify a peptide which permits or facilitates the transport of an active agent through a human or animal tissue.

## Claims

### Claim 1

A method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue, comprising the steps of:
(a) administering in vivo or in situ to a site in an animal a predetermined amount of phage from a random phage library or a preselected phage library;
(b) at a predetermined time harvesting phage from the animal to select transported phage, wherein the harvesting site is separated from the site of administration by a tissue barrier,
(c) amplifying the transported phage in a host;
(d) repeating in order step (a) using the transported phage obtained in step (b) and amplified in step (c) and steps (b) and (c) a predetermined number of times to obtain a selected phage library containing phage which can be transported from the site of administration to the site of harvesting; and
(e) determining the identity of at least one peptide coded by phage in the selected phage library to identify a peptide which permits or facilitates the transport of an active agent through a human or animal tissue.

### Claim 2 (depends on 1)

The method of claim 1, wherein step (d) is repeated from 0 to 30 times.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tissue barrier is selected from the group consisting of duodenum tissue, jejunum tissue, ilium tissue, ascending colon tissue, transverse colon tissue, desending colon tissue, pelvic colon tissue, tissue in the vascular endothelium which lines the vascular system, tissue in the vascular endothelium of the blood brain barrier, vascular smooth muscle tissue, alveolar tissue, liver tissue, kidney tissue, bone marrow tissue, heart tissue, spleen tissue, pancreas tissue, thymus tissue, brain tissue, spinal tissue, neuronal tissue, retinal eye tissue or combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tissue barrier comprises epithelial cells lining the lumenal side of the gastrointestinal track.

### Claim 5 (depends on 4)

The method of claim 4, wherein the tissue barrier comprises the colon tissue.

### Claim 6 (depends on 1)

The method of claim 1, wherein the phage is administered to the gastro-intestinal tract and is harvested from portal blood.

### Claim 7 (depends on 1)

The method of claim 1, wherein the phage is administered to the gasto-intestinal tract and is harvested from systemic blood.

### Claim 8 (depends on 1)

The method of claim 1, wherein the active agent is a drug or antigen.

### Claim 9 (depends on 1)

The method of claim 1, wherein the active agent is a nano- or microparticle.

### Claim 10 (depends on 9)

The method of claim 9, wherein the peptide is coated onto or adsorbed onto or covalently bonded to the surface of the nano-or microparticle.

### Claim 11 (depends on 9)

The method of claim 9, wherein the nano- or microparticle is formed from the peptide.

### Claim 12 (depends on 9)

The method of any of claims 9, wherein the nano- or microparticle is a drug-loaded or drug-encapsulated nano- or microparticle.

### Claim 13

A method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue, comprising the steps of:
(a) administering in vivo or in situ to the gastro-instestinal tract of an animal a predetermined amount of phage from a random phage library or a preselected phage library;
(b) at a predetermined time harvesting phage which is transported to the portal circulatory system or to the systemic circulatory system of the animal to select transported phage;
(c) amplifying the transported phage in a host;
(d) repeating in order step (a) using the transported phage obtained in step (b) and amplified in step (c) and steps (b) and (c) a predetermined number of times to obtain a selected phage library containing phage which can be transported from the gastrointestinal tract to the portal circulatory system or to the systemic circulatory system of the animal; and
(e) determining the identity of at least one peptide coded by phage in the selected phage library to identify a peptide which permits or facilitates the transport of an active agent through a human or animal tissue.

### Claim 14

A peptide which permits or facilitates the transport of an active agent through a human or animal tissue, the peptide being identified by a method comprising the steps of:
(a) administering in vivo or in situ to a site in an animal a predetermined amount of phage from a random phage library or a preselected phage library;
(b) at a predetermined time harvesting phage from the animal to select transported phage, wherein the harvesting site is separated from the site of administration by a tissue barrier,
(c) amplifying the transported phage in a host;
(d) repeating in order step (a) using the transported phage obtained in step (b) and amplified in step (c) and steps (b) and (c) a predetermined number of times to obtain a selected phage library containing phage which can be transported from the site of administration to the site of harvesting; and
(e) determining the identity of at least one peptide coded by phage in the selected phage library to identify a peptide which permits or facilitates the transport of an active agent through a human or animal tissue.

### Claim 15 (depends on 14)

The peptide of claim 14, wherein step (d) is repeated from 0 to 30 times.

### Claim 16 (depends on 14)

The peptide of claim 14, wherein the tissue barrier comprises duodenum tissue, jejunum tissue, ilium tissue, ascending colon tissue, transverse colon tissue, desending colon tissue, pelvic colon tissue, tissue in the vascular endothelium which lines the vascular system, tissue in the vascular endothelium of the blood brain barrier, vascular smooth muscle tissue, alveolar tissue, liver tissue, kidney tissue, bone marrow tissue, heart tissue, spleen tissue, pancreas tissue, thymus tissue, brain tissue, spinal tissue, neuronal tissue, retinal eye tissue or combinations thereof.

### Claim 17 (depends on 14)

The peptide of claim 14, wherein the tissue barrier comprises epithelial cells lining the lumenal side of the gastro-intestinal track.

### Claim 18 (depends on 17)

The peptide of claim 17, wherein the tissue barrier comprises colon tissue.

### Claim 19 (depends on 14)

The peptide of claim 14, wherein the phage is administered to the gastro-intestinal tract and is harvested from portal blood.

### Claim 20 (depends on 14)

The peptide of claim 14, wherein the phage is administered to the gastro-intestinal tract and is harvested from systemic blood.

### Claim 21 (depends on 14)

The peptide of claim 14, wherein the active agent is a drug or antigen.

### Claim 22 (depends on 14)

The peptide of claim 14, wherein the active agent is a nano- or microparticle.

### Claim 23 (depends on 22)

The peptide of claim 22, wherein the peptide is coated onto or adsorbed onto or covalently bonded to the surface of the nano-or microparticle.

### Claim 24 (depends on 22)

The peptide of claim 22, wherein the nano- or microparticle is formed from the peptide.

### Claim 25 (depends on 22)

The peptide of claim 22, wherein the nano- or microparticle is a drug-loaded or drug-encapsulated nano- or microparticle.

### Claim 26

A method of identifying a peptide motif which when present in a peptide permits or facilitates the transport of an active agent through a human or animal tissue, comprising the steps of:
(a) administering in vivo or in situ to a site in an animal a predetermined amount of phage from a random phage library or a preselected phage library;
(b) at a predetermined time harvesting phage from the animal to select transported phage, wherein the harvesting site is separated from the site of administration by a tissue barrier,
(c) amplifying the transported phage in a host;
(d) repeating in order step (a) using the transported phage obtained in step (b) and amplified in step (c) and steps (b) and (c) a predetermined number of times to obtain a selected phage library containing phage which can be transported from the site of administration to the site of harvesting; and
(e) determining the identity of a plurality of peptides coded by phage in the selected phage library to identify a peptide motif common to at least two of the peptides which permit or facilitate the transport of an active agent through a human or animal tissue.

### Claim 27

A method of identifying a peptide which permits or facilitates the internalization of an active agent into human or animal tissue, comprising the steps of:
(a) administering in vivo or in situ to a site adjacent a selected tissue in an animal a predetermined amount of phage from a random phage library or a preselected phage library;
(b) at a predetermined time harvesting phage from the selected tissue to select tissue internalized phage, wherein the harvesting comprising the steps of:
(i) homognizing the selected tissue to obtain a homogenate: and
(ii) washing the homogenate;
(c) amplifying the tissue internalized phage in a host;
(d) determining the identity of at least one peptide coded by tissue internalized phage to identify a peptide which permits or facilitates the internalization of an active agent into a human or animal tissue or transport of the active agent through human or animal tissue.

### Claim 28 (depends on 27)

The method of claim 27, wherein the preselected phage library comprises tissue internalized phage.

### Claim 29 (depends on 27)

The method of claim 27, wherein the selected tissue is selected from the group consisting of duodenum, jejunum, ilium, ascending colon, transverse colon, desending colon, pelvic colon, vascular endothelium which lines the vascular system, vascular endothelium of the blood brain barrier, vascular smooth muscle, alveolar, liver, kidney, bone marrow, heart, spleen, pancreas, thymus, brain, spinal cord, neuronal or retinal eye tissue.

### Claim 30

A method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue, comprising the steps of:
(a) administering in vivo or in situ to a site adjacent a selected tissue in an animal a predetermined amount of phage from a random phage library or a preselected phage library;
(b) at a predetermined time harvesting phage from the selected tissue to obtain tightly bound phage, wherein the harvesting comprises the steps of:
(i) washing the selected tissue to obtain washed tissue; and
(ii) homogenized the washed tissue
(c) amplifying the tightly bound phage in a host; and
(d) determining the identity of at least one peptide coded by tightly bound phage to identify a peptide which permits or facilitates the internalization of an active agent into a human or animal tissue.

### Claim 31 (depends on 30)

The method of claim 30, wherein the preselected phage library comprises tightly bound phage.

### Claim 32 (depends on 30)

The method of claim 30, wherein the selected tissue is selected from the group consisting of duodenum, jejunum, ilium, ascending colon, transverse colon, desending colon, pelvic colon, vascular endothelium which lines the vascular system, vascular endothelium of the blood brain barrier, vascular smooth muscle, alveolar, liver, kidney, bone marrow, heart, spleen, pancreas, thymus, brain, spinal cord, neuronal or retinal eye tissue.

### Claim 33 (depends on 1)

The method of claim 1, wherein the phage is administered to the gastrointestinal tract and is harvested from brain tissue.

### Claim 34 (depends on 1)

The method of claim 1, wherein the havesting site is tissue selected from the group consisting of duodenum, jejunum, ilium, ascending colon, transverse colon, desending colon, pelvic colon, vascular endothelium which lines the vascular system, vascular endothelium of the blood brain barrier, vascular smooth muscle, alveolar; liver, kidney, bone marrow, heart, spleen, pancreas, thymus, brain, spinal cord, neuronal or retinal eye tissue.

### Claim 34 (depends on 14)

The peptide of claim 14, wherein the havesting site is tissue selected from the group consisting of duodenum, jejunum, ilium, ascending colon, transverse colon, desending colon, pelvic colon, vascular endothelium which lines the vascular system, vascular endothelium of the blood brain barrier, vascular smooth muscle, alveolar, liver, kidney, bone marrow, heart, spleen, pancreas, thymus, brain, spinal cord, neuronal or retinal eye tissue.

### Claim 35

A method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue, comprising the steps of:
(a) administering in vivo or in situ to the gastro-instestinal tract of an animal a predetermined amount of phage from a random phage library or a preselected phage library;
(b) at a predetermined time harvesting phage which is transported to the brain tissue of the animal to select transported phage;
(c) amplifying the transported phage in a host;
(d) repeating in order step (a) using the transported phage obtained in step (b) and amplified in step (c) and steps (b) and (c) a predetermined number of times to obtain a selected phage library containing phage which can be transported from the gastrointestinal tract to the brain tissue of the animal; and
(e) determining the identity of at least one peptide coded by phage in the selected phage library to identify a peptide which permits or facilitates the transport of an active agent through a human or animal tissue.

### Claim 35

A peptide comprising SEQ ID NO: 19 or a fragment thereof which contains at least 6 amino acid residues.

### Claim 36 (depends on 14)

The peptide of claim 14, wherein the phage is administered to the gastrointestinal tract and is harvested from brain tissue.

### Claim 36

A peptide comprising SEQ ID NO: 21 or a fragment thereof which contains at least 6 amino acid residues.

### Claim 37

A peptide comprising SEQ ID NO: 23 or a fragment thereof which contains at least 6 amino acid residues.

### Claim 37

A peptide comprising SEQ ID NO: 25 or a fragment thereof which contains at least 6 amino acid residues.

### Claim 38

A peptide comprising SEQ ID NO: 27 or a fragment thereof which contains at least 6 amino acid residues.

### Claim 39

A peptide comprising SEQ ID NO: 29 or a fragment thereof which contains at least 6 amino acid residues.

### Claim 40

A peptide comprising SEQ ID NO: 31 or a fragment thereof which contains at least 6 amino acid residues.

### Claim 41

A peptide comprising SEQ ID NO: 33 or a fragment thereof which contains at least 6 amino acid residues.
